Ruti Aga's six-year ban: a fake prescription from a relative cost more than the positive test

A prescription bears the stamp of a clinic. When the Athletics Integrity Unit called the number printed on it, the clinic replied that it had never issued the document. The name signed in the doctor's field belonged to a relative of the athlete, who held no medical registration. That person claimed to have used an old prescription pad taken from a former workplace; the workplace confirmed it had never employed anyone by that name. Three independent verifications, three collapses. Ruti Aga, 32, an Ethiopian marathon runner, has received a six-year ban beginning on 10 September. Two years for the presence of a prohibited substance in her sample. Four years for tampering with evidence. Served consecutively, not concurrently. I read this decision the way I read the split chart of a post-injury comeback: looking for the gap between what is declared and what is measured. What was declared was a knee treatment. What was measured was a medical file that does not exist. Aga belongs to the top tier of women's road running. The 2026 Tokyo Marathon title and three runner-up finishes at World Marathon Majors place her among the marathon elite for the 2026–2026 window. In March she won a half marathon in China. That race is the trigger point for this entire file. Her sample returned an adverse finding for methylprednisolone. Aga attributed the substance to treatment for a knee injury. A data limitation must be stated immediately: the published source gives no specific date for the March half marathon, no year for the sample collection, and no year for the provisional suspension. For an analysis of a sanction, that is a significant gap, because any inference about how much of the substance remained in the body at the time of competition depends on the timeline. I record this as insufficient data rather than filling it with speculation. The perfectionist's delay, it turns out, is a form of precision. Her professional context also needs to be placed correctly. For an East African marathoner at World Marathon Major level, income comes from three sources: appearance fees, prize money, and sponsorship contracts. Road races in China account for a meaningful share of the first stream, because the volume of events is high and appearance fees are competitive. That is why an athlete at her peak still accepts a regional half marathon in March, in the middle of preparation for the main marathon season. Methylprednisolone is a synthetic glucocorticoid, a corticosteroid. It sits in WADA class S9, is prohibited in competition, and is classified as a Specified Substance. Those three properties define the entire sanction framework, and each needs decoding separately. Class S9 is entirely different from anabolic steroids. Corticosteroids are anti-inflammatory drugs, commonly used in knee joint injections, peri-articular injections, and the treatment of tendinitis and bursitis. In endurance sport, this drug class appears routinely in athletes' medical records. Calling it a "steroid," as many reports still do, is a technical error with clear consequences: it lifts a case of mismanaged medication onto the same scale as systemic doping, and blurs what actually deserves discussion. The in-competition-only rule opens a fairly wide legal path. An injection outside the competition period, with sufficient washout time and complete records in the medical file, is an entirely legitimate route. The length of the detection window depends on route of administration, dose and individual metabolism, which is precisely why timing the injection is the medical team's responsibility, not the athlete's. A knee injection three weeks before competition and one seven days before competition can produce two opposite legal outcomes from an identical treatment protocol. A Specified Substance carries a lower baseline: two years, with room for reduction if it can be shown the substance was not used to enhance performance. This is the most important point in the whole file. The substance side was always the softer half of Aga's story. A retroactive TUE application, or an honest disclosure of a therapeutic error, would very likely have brought the case down to no violation at all, or to a substantially reduced sanction. The hard part sits in the additional four years. The WADA Code treats tampering during results management as an independent violation with a four-year baseline; and when an athlete commits multiple violations, the sanctions are served consecutively rather than concurrently. Aga was charged twice, and the two charges cannot be merged. What stands out is how the Athletics Integrity Unit verified the document. The agency did not stop at reading the paper. It called the clinic named on the prescription directly, checked the registration number of the signatory, and contacted the facility where that person claimed to have worked. All three steps are cheap and fast. The barrier to faking a medical document in elite sport has effectively disappeared, not because athletes have become better, but because verification has become a default procedure. I once built a manual injury tracking sheet for the final eight J2 matches of Nagoya Grampus, hand-recording 37 loss-of-control sequences involving centre-backs returning from injury. Nagoya taught me that the manual spreadsheet is where data first learns to speak. That lesson applies here in reverse: a medical file is also a spreadsheet, and it is only as trustworthy as the quality of each row entered into it. Aga's prescription had three rows, and all three were wrong. For someone who analyses injuries, this is the section that stops me longest. A post-injury comeback always carries two kinds of risk: the risk of the body and the risk of the file. The body never betrays anyone; it only reflects what we chose to ignore. The file behaves the same way. A mistyped date, an undeclared injection, an unverified prescription — those small cracks appear before the test result appears, only nobody records them. 112 days of sporting silence, and what I hear most clearly is the cracking of the body; the silence between sample collection and the announcement of the sanction works the same way, it does not erase the data, it only delays reading it. Aga's sanction has a very clear architecture: two years for the positive test, four years for the fabrication. The cover-up was punished at twice the rate of the offence. In every risk model I have built for an athlete, the cost of concealment is always treated as a variable with a long-tailed distribution, and this is a data point that confirms it. There is a derivative risk that rarely gets discussed. When a case ends with a finding of evidence tampering, the case for retrospective review of older samples becomes reasonable. Long-term storage samples and athlete biological passports exist for exactly this purpose. The published source does not address whether such a review is underway, so I leave it as an open hypothesis rather than a conclusion. The responsibility of the relative who signed the prescription also falls outside the document, though in practice that layer of people is usually the next link investigated. The common reading is that another cheating athlete has been caught. That reading misses the most important point. The material of the fabrication is itself a diagnosis. A clinic that does not exist. A relative with no medical registration. An old prescription pad. All of those details belong to an amateur cover-up, carried out by people with no compliance expertise, rather than to an organised doping operation. That amateurism points to something specific: the medical and legal support structure around this athlete was very thin. In the East African road-running system, athletes usually have a coach, an agent, a familiar clinic. They rarely have a dedicated compliance advisor — someone who knows that a retroactive TUE application is a real procedure, that honestly disclosing a therapeutic error can lead to a far lighter sanction than constructing a fake file. Had Aga had that person beside her, this file might have read in a completely different direction: a corticosteroid injection for knee arthritis, declared late, handled administratively. The sanction also does not shift the competitive balance of women's marathon. Ethiopia has a bench deep enough to fill a vacancy almost instantly. To the national pathway, Aga is a replaceable node. To her, it is an entire career. The distance between those two magnitudes of loss explains why individual cases rarely produce systemic change: the damage is concentrated in one person, while the benefit of tighter rules is spread across the whole industry. There is one more narrative risk worth flagging. Calling methylprednisolone a "steroid" leads the public to picture an anabolic doping case, when the reality is an anti-inflammatory corticosteroid used outside protocol and then concealed. Those two stories lead to two different lessons. The first is about intent to cheat, and that lesson cannot be fixed by training. The second is about compliance capacity, and that lesson can be. Aga will become eligible again at 38. The probability of returning to World Marathon Major podium level after a six-year competitive layoff at that age is very low, and I do not need more data to say so. What I want to put on the other side of the scale is different: a 32-year-old at the peak of her professional value lost her career to a paperwork procedure more than to a prohibited substance. Those six years are a measure of how thick the support system behind a medal really is. And if there is another Ethiopian athlete today injecting a corticosteroid into a knee, wondering what she is required to declare, who will be the one to answer?